Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PIAS1 Promotes Lymphomagenesis through MYC Upregulation.
Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP. Rabellino A, et al. Among authors: tompkins vs. Cell Rep. 2016 Jun 7;15(10):2266-2278. doi: 10.1016/j.celrep.2016.05.015. Epub 2016 May 26. Cell Rep. 2016. PMID: 27239040 Free PMC article.
NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S. Han SS, et al. Among authors: tompkins vs. Mol Cancer. 2010 Apr 30;9:97. doi: 10.1186/1476-4598-9-97. Mol Cancer. 2010. PMID: 20433747 Free PMC article.
Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells.
Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S. Han SS, et al. Among authors: tompkins vs. Biochem Biophys Res Commun. 2013 Jul 12;436(4):660-5. doi: 10.1016/j.bbrc.2013.06.012. Epub 2013 Jun 11. Biochem Biophys Res Commun. 2013. PMID: 23764397 Free PMC article.
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S. Duncan K, et al. Among authors: tompkins vs. Blood Cancer J. 2013 Nov 29;3(11):e165. doi: 10.1038/bcj.2013.61. Blood Cancer J. 2013. PMID: 24292417 Free PMC article.
37 results